Human papilloma virus as predictor of cancer prognosis
Inventors
Boshoff, Chris Hendrik • Fenton, Timothy Robert • Lechner, Matthias Alexander • Stephens, Philip James • Hawryluk, Matthew J. • Frampton, Garrett Michael • Yelensky, Roman
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11766439-B2
Publication Date
2023-09-26
Expiration Date
Abstract
Methods of treating a head and neck cancer are disclosed.
Core Innovation
The invention describes generating a personalized cancer treatment report for a subject with squamous cell carcinoma of the head and neck (HNSCC) by using human papillomavirus (HPV) status to guide therapy selection. A sample from the subject is acquired and a determination is made whether the subject is HPV− or HPV+. Based on the HPV status, a treatment is selected with the intent to tailor therapy to the subject’s HPV classification.
For HPV+ subjects, the treatment selection includes a mammalian target of rapamycin (mTOR) inhibitor, a phosphatidylinositol-3 kinase (PI3K) inhibitor, or a PI3K/mTOR inhibitor. For HPV− subjects, a CDK inhibitor is selected as the treatment. The selected treatment is then memorialized by generating the personalized cancer treatment report.
The described approach further supports stratification and report content by using additional determinations related to specific pathway or gene alterations and by incorporating additional information in the report. The report can include information associated with HPV status and can further include items such as prognosis, responsiveness-related information, resistance-related information, potential therapeutic options, likely effectiveness and acceptability/advisability, and drug administration information.
Claims Coverage
The independent claims cover a personalized reporting method that determines whether a subject with HNSCC is HPV− or HPV+, selects a treatment class accordingly, and generates a report that memorializes the selected treatment. The coverage centers on HPV-status-driven therapy selection using mTOR/PI3K/PI3K-mTOR inhibitors for HPV+ and CDK inhibitors for HPV−, with dependent limitations adding additional stratification and report information.
Personalized cancer treatment report generation for HPV-status guided HNSCC therapy
Acquiring a sample from a subject having squamous cell carcinoma of the head and neck (HNSCC); determining whether the subject is HPV− or HPV+; selecting a treatment based on whether the subject is HPV− or HPV+, wherein if the subject is HPV+, a mammalian target of rapamycin (mTOR) inhibitor, a phosphatidylinositol-3 kinase (PI3K) inhibitor, or a PI3K/mTOR inhibitor is selected as a treatment, and wherein if the subject is HPV−, a CDK inhibitor is selected as a treatment; and generating the personalized cancer treatment report to memorialize the selected treatment.
Overall, the claim coverage is anchored in using HPV status (HPV− versus HPV+) to drive treatment class selection for HNSCC and in generating a personalized cancer treatment report that memorializes the selected treatment. Dependent coverage further refines HPV-detection sample types, enumerates concrete inhibitor options for the selected treatment branch, and can add mutation-based stratification and expanded report content such as prognosis, resistance, therapeutic option information, and drug administration information.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?